Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2025CancersOpen Access

Drivers of Pancreatic Cancer: Beyond the Big 4

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLaura PorczaRBRafael Ballesteros-CilleroLLLok To Lam

Discussion

Loading...

Member takes

Overview

Review identifies loss of PTEN and other proteins as significant in PDAC, suggesting new therapeutic targets.

Key Points

  • MAIN FINDING: The review emphasizes the role of non-genetic factors in pancreatic cancer, particularly PTEN loss.
  • KEY EVIDENCE: More than half of PDAC cases show loss of PTEN protein despite low genetic mutation rates.
  • APPROACH: The analysis includes immunohistochemical studies examining protein expression in PDAC cases.
  • SIGNIFICANCE: Understanding these pathways opens new avenues for treatment strategies beyond traditional targets.

Cite This Study

Porcza et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc8a0https://doi.org/10.3390/cancers17142354
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy2024 · 26 citations
  2. 2KRAS: the Achilles’ heel of pancreas cancer biology2025 · 44 citations
  3. 3KRAS and Beyond: Emerging Targeted and Molecularly Stratified Strategies in Pancreatic Ductal Adenocarcinoma2026
  4. 4Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here2026 · 3 citations
  5. 5Pancreatic Cancer: Translating Tumor Biology into Actionability2026 · 1 citations